AXGT - Axovant Gene Therapies Ltd.
| Previous Close | 5.17 |
| Open | 5.12 |
| Bid | 5.01 x 1800 |
| Ask | 5.03 x 1100 |
| Day's Range | 4.91 - 5.22 |
| 52 Week Range | 3.81 - 19.60 |
| Volume | 87,834 |
| Avg. Volume | 137,492 |
| Market Cap | 114.642M |
| Beta (3Y Monthly) | 1.22 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.19 |
| Earnings Date | Nov 8, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 23.29 |
- GlobeNewswire
Axovant Announces Amendment to Credit Facility with Hercules Capital
Axovant Gene Therapies Ltd. (AXGT), a clinical-stage company developing innovative gene therapies, today announced the completion of an amendment to its loan and security agreement with Hercules Capital, Inc. (“Hercules”). The amendment provides for a 9-month interest-only period commencing December 2019, as well as the elimination of the covenant to maintain a minimum cash balance.
- Zacks
Axovant's GM1 Gangliosidosis Candidate Gets Orphan Drug Tag
The FDA grants Orphan Drug status to Axovant's (AXGT) gene therapy candidate, AXO-AAV-GM1, being developed for the treatment of GM1 gangliosidosis. Shares decline despite the positive news.
- GlobeNewswire
Axovant Gene Therapies Receives Orphan Drug Designation from FDA for AXO-AAV-GM1 for the Treatment of GM1 Gangliosidosis
Axovant Gene Therapies Ltd. (AXGT), a clinical-stage company developing innovative gene therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the Company’s investigational gene therapy, AXO-AAV-GM1, for the treatment of GM1 gangliosidosis. GM1 gangliosidosis is a progressive and fatal pediatric lysosomal storage disorder caused by mutations in the GLB1 gene leading to impaired production of the beta-galactosidase enzyme. “We are pleased to receive orphan drug designation for our GM1 gangliosidosis program as we advance the development of this potentially transformative, one-time gene therapy,” said Dr. Gavin Corcoran, chief R&D officer at Axovant.
- Zacks
Axovant Gene Therapies Enters Oversold Territory
Axovant Gene Therapies has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
- Zacks
Axovant (AXGT) Moves to Strong Buy: Rationale Behind the Upgrade
Axovant (AXGT) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- GlobeNewswire
Axovant Announces Corporate Updates and Financial Results for Second Fiscal Quarter Ended September 30, 2019
First evidence of clinical stabilization in two children with Tay-Sachs disease that received AXO-AAV-GM2 presented at ESGCT in October 2019Continued enrollment of patients in.
- GlobeNewswire
Axovant Gene Therapies Announces Investor Conference Presentations for the Remainder of 2019
A live webcast of the Jefferies and Piper Jaffray conference presentations will be available in the Events section of Axovant's website at www.axovant.com. Replays will be available for approximately 30 days following the conference.
- GlobeNewswire
Axovant Presents First Evidence of Clinical Stabilization in Tay-Sachs Disease at the European Society of Gene and Cell Therapy 27th Annual Congress
Axovant Gene Therapies Ltd. (AXGT), a clinical-stage company developing innovative gene therapies, today announced preliminary data from an expanded access study administering investigational AXO-AAV-GM2 gene therapy in two patients with infantile Tay-Sachs disease (TSD) at the 27th Annual Congress of the European Society of Gene and Cell Therapy. Infantile TSD, a rapidly progressive and fatal pediatric neurodegenerative genetic disorder, has a median life expectancy of approximately 3-4 years. This data indicates the potential to modify the rate of disease progression in children with infantile TSD.
- Benzinga
The Week Ahead In Biotech: Earnings Trickle In, While Glaxo, Melinta, Foamix And Eton Await FDA Verdict
Biotech stocks saw some strength last week. Positive clinical readouts, a couple of M&A deals and hopes of drug companies clinching a broader opioid settlement agreement worked in favor of the sector. ...
- GlobeNewswire
Axovant Gene Therapies Announces Upcoming Presentations at the European Society of Gene and Cell Therapy 27th Annual Congress
Axovant Gene Therapies, Ltd. (AXGT), a clinical-stage company developing innovative gene therapies, today announced upcoming presentations regarding its investigational gene therapy programs, AXO-Lenti-PD, AXO-AAV-GM1 and AXO-AAV-GM2, at the European Society of Gene and Cell Therapy (ESGCT) 27th Annual Congress, held in Barcelona, Spain, October 22-25, 2019.
- Zacks
Axovant (AXGT) Upgraded to Buy: Here's What You Should Know
Axovant (AXGT) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Zacks
Axovant (AXGT) Gains As Market Dips: What You Should Know
In the latest trading session, Axovant (AXGT) closed at $6.61, marking a +0.46% move from the previous day.
- GlobeNewswire
Axovant Gene Therapies to Present at 2019 Cell & Gene Meeting on the Mesa
BASEL, Switzerland, Sept. 25, 2019 -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT), a clinical-stage company developing innovative gene therapies, today announced that Parag.
- Zacks
Axovant (AXGT) Stock Moves -1.31%: What You Should Know
Axovant (AXGT) closed at $7.53 in the latest trading session, marking a -1.31% move from the prior day.
- Simply Wall St.
Axovant Gene Therapies Ltd. (NASDAQ:AXGT): What Does Its Beta Value Mean For Your Portfolio?
If you're interested in Axovant Gene Therapies Ltd. (NASDAQ:AXGT), then you might want to consider its beta (a measure...
- Benzinga
Axovant Analyst Turns Bullish Ahead Of Q4 Gene Therapy Data Readouts
Axovant's multiple opportunities to find an efficacious gene therapy make it an attractive investment ahead of data readouts scheduled for the fourth quarter, Skorney said in a Monday note. Axovant is due to release initial data from the first Type 2 GM1 gangliosidosis patient dosed with AXO-AAV-GM1 in the fourth quarter. The analyst said the simplistic approach used by AXO-AAV-GM1 in gangliosidosis — usage of well-known AAV9 vector and the IV route of administration — improves the chances of its clinical success.
- GlobeNewswire
Axovant Announces Corporate Updates and Financial Results for First Fiscal Quarter Ended June 30, 2019
SUNRISE-PD Phase 2 trial of AXO-LENTI-PD for Parkinson's disease continues to enroll patients in second dose cohort with data expected in the fourth quarter of calendar 2019Data.
- Zacks
Immunomedics (IMMU) Posts Wider-Than-Expected Loss in Q2
Immunomedics (IMMU) posts wider-than-expected loss and generates no revenues in the second quarter of 2019.
- Zacks
Horizon Therapeutics' (HZNP) Q2 Earnings Beat Estimates
Horizon (HZNP) beats earnings and sales estimates in the second quarter of 2019.
- Zacks
Catalyst's (CPRX) Q2 Earnings and Revenues Beat Estimates
Catalyst (CPRX) surpasses earnings and sales estimates in the second quarter of 2019.
- Zacks
Geron (GERN) Stock Up Despite Q2 Earnings & Sales Miss
Geron (GERN) posts a wider-than-expected loss in second-quarter 2019. Operating expenses increase on a year-over-year basis.
- Zacks
IVERIC bio's (ISEE) Q2 Loss Narrows, Gene Therapy in Focus
IVERIC bio (ISEE) second-quarter earnings improve year over year. The company is focusing on developing gene therapies for treating inherited retinal diseases.
- Zacks
Clovis (CLVS) Q2 Earnings & Sales Lag Estimates, Shares Down
Clovis (CLVS) reports dismal second-quarter 2019 results. The company provides lower-than-expected guidance for product sales in 2019.
